AUS
NZ
UK
CA
USA
IND
Faron Pharmaceuticals Ltd. (AIM:FARN), a clinical-stage biopharmaceutical company focused on pioneering CLEVER-1 receptor-targeting approaches to enhance anti-tumor immunity in treatment-resistant cancers, has announced the appointment of Dr. Petri Bono (M.D., Ph.D.) as its new Chief Medical Officer (CMO), effective from 15 August 2024.
Dr. Bono's Extensive Background
Dr. Bono brings a wealth of experience to Faron Pharmaceuticals, having previously served as Chief Medical Officer and a member of the executive team at Terveystalo, Finland's largest private healthcare service provider. His prior roles include Chief Medical Officer at Helsinki University Hospital, where he also held positions as Associate Professor of Cancer Biology and Director of the Comprehensive Cancer Center. Dr. Bono's leadership in oncology includes participation in numerous trials from Phase 1 to 3, particularly in immuno-oncology, and he has contributed 102 peer-reviewed papers to prestigious journals such as the New England Journal of Medicine, Lancet Oncology, JAMA, and Cancer Cell.
Strategic Fit with Faron's Mission
Dr. Bono’s extensive background in molecular and immunological oncology aligns seamlessly with Faron Pharmaceuticals' mission. His experience in translational and clinical studies of targeted therapies and immunology positions him uniquely to advance Faron's immuno-oncology programs. Faron is dedicated to developing novel myeloid cell-targeting immunotherapies, with the aim of expanding the reach of immunotherapy to broader patient populations, particularly within the solid tumor space.
Anticipated Impact
Faron Pharmaceuticals anticipates that Dr. Bono's expertise will significantly bolster its immuno-oncology program. His leadership is expected to drive forward the company's innovative approaches in tackling cancers, particularly those resistant to current treatments. With his proven track record in oncology research and clinical trials, Dr. Bono is poised to make a substantial impact on the company's ongoing and future therapeutic developments.
